Syros Pharmaceuticals, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.85 | -$0.85 | -$0.85 |
Q2 2024 | 1 | -$0.77 | -$0.77 | -$0.77 |
Q3 2024 | 4 | -$0.79 | -$0.50 | -$0.68 |
Q4 2024 | 1 | -$0.70 | -$0.70 | -$0.70 |
Q1 2025 | 2 | -$0.75 | -$0.75 | -$0.75 |
Q2 2025 | 2 | -$0.79 | -$0.79 | -$0.79 |
Q3 2025 | 2 | -$0.81 | -$0.81 | -$0.81 |
Q4 2025 | 2 | -$0.87 | -$0.87 | -$0.87 |
Syros Pharmaceuticals, Inc. Earnings Date And Information
Syros Pharmaceuticals, Inc. last posted its earnings results on Wednesday, July 31st, 2024. The company reported $-0.7 earnings per share for the quarter, topping analysts' consensus estimates of $-0.79 by $0.09. The company had revenue of 0 for the quarter and had revenue of 9.94 M for the year. Syros Pharmaceuticals, Inc. has generated $-6 earnings per share over the last year ($-5.81 diluted earnings per share) and currently has a price-to-earnings ratio of -0.6. Syros Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 11th, 2024 based on prior year's report dates.
Syros Pharmaceuticals, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
07/31/2024 | Q2 2024 | -$0.79 | -$0.59 | 0.2 | $460,000 | $0 |
05/14/2024 | Q1 2024 | -$0.89 | -$0.10 | 0.79 | $0 | |
03/27/2024 | Q4 2023 | -$1.23 | -$2.18 | -0.95 | $386,000 | |
11/14/2023 | Q3 2023 | -$1.12 | -$1.43 | -0.31 | $3.94 M | $3.76 M |
08/08/2023 | Q2 2023 | -$1.11 | -$1.30 | -0.19 | $3.50 M | $2.83 M |
05/10/2023 | Q1 2023 | -$1.12 | -$0.54 | 0.58 | $2.95 M | |
03/02/2023 | Q4 2022 | -$1.27 | $0.99 | 2.26 | $-5,467,000 | |
11/14/2022 | Q3 2022 | -$3.91 | -$2.24 | 1.67 | $5.18 M | $3.89 M |
08/09/2022 | Q2 2022 | -$4.20 | -$5.51 | -1.31 | $4.74 M | $6.28 M |
05/16/2022 | Q1 2022 | -$4.80 | -$3.75 | 1.05 | $5.47 M | |
03/15/2022 | Q4 2021 | -$4.40 | -$3.78 | 0.62 | $7.80 M | |
11/05/2021 | Q3 2021 | -$4.30 | -$4.14 | 0.16 | $4.49 M | $5.70 M |
08/05/2021 | Q2 2021 | -$3.60 | -$3.60 | 0 | $4.13 M | $5.16 M |
05/06/2021 | Q1 2021 | -$5.50 | -$2.32 | 3.18 | $4.83 M | |
03/04/2021 | Q4 2020 | -$5.40 | -$4.91 | 0.49 | $5.70 M | |
11/05/2020 | Q3 2020 | -$3.80 | -$4.26 | -0.46 | $2.54 M | $3.83 M |
08/06/2020 | Q2 2020 | -$4.00 | -$3.76 | 0.24 | $1.90 M | $3.19 M |
05/07/2020 | Q1 2020 | -$4.50 | -$3.92 | 0.58 | $2.38 M | |
03/05/2020 | Q4 2019 | -$4.70 | -$4.60 | 0.1 | $508,000 | |
11/12/2019 | Q3 2019 | -$4.80 | -$4.66 | 0.14 | $441,167 | $558,000 |
Syros Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Syros Pharmaceuticals, Inc.'s earnings date?
Syros Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 11th, 2024 based off last year's report dates.
-
Did Syros Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Syros Pharmaceuticals, Inc. (:SYRS) reported $-0.7 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.79 by $0.09.
-
How can I listen to Syros Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Syros Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Syros Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Syros Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Syros Pharmaceuticals, Inc. generate each year?
Syros Pharmaceuticals, Inc. (:SYRS) has a recorded annual revenue of $9.94 M.
-
How much profit does Syros Pharmaceuticals, Inc. generate each year?
Syros Pharmaceuticals, Inc. (:SYRS) has a recorded net income of $9.94 M. Syros Pharmaceuticals, Inc. has generated $-5.81 earnings per share over the last four quarters.
-
What is Syros Pharmaceuticals, Inc.'s price-to-earnings ratio?
Syros Pharmaceuticals, Inc. (:SYRS) has a price-to-earnings ratio of -0.6 and price/earnings-to-growth ratio is -0.03.